|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
HEMATOPOIESIS
From the Division of Hematology/Oncology, the Hospital
for Sick Children and Department of Medical Oncology and Hematology,
University Health Network, University of Toronto, Ontario, Canada, and
Department of Haematology, Royal Manchester Children's Hospital,
United Kingdom.
Our inability to purify hematopoietic stem cells (HSCs) precludes
direct study of many aspects of their behavior in the clinical hematopoietic stem cell transplantation (HSCT) setting. We indirectly assessed stem/progenitor cell behavior in the first year after HSCT by
examining changes in neutrophil telomere length, X-inactivation ratios,
and cycling of marrow progenitors in 25 fully engrafted allogeneic HSCT
recipients. Donors were sampled once and recipients at engraftment and
2 to 6 months and 12 months after HSCT. Telomere length was measured by
an in-gel hybridization technique, X-inactivation ratios were measured
by the human androgen receptor assay, and cell cycle status was
determined by flow cytometric analysis of pyronin Y- and Hoechst
33342-stained CD34+CD90+ and
CD34+CD90 Hematopoietic stem cell transplantation (HSCT) is
increasingly used to treat patients with a variety of malignant and
nonmalignant diseases. Its clinical application has evolved in the
absence of rigorous understanding of many aspects of its biology. In
particular, the phenomena of engraftment and hematopoietic
reconstitution remain poorly understood.
The marrow repopulating hematopoietic stem cells (HSCs) in an allograft
represent a small fraction of the donor's HSCs, yet they are required
to reconstitute hematopoiesis and sustain it for the lifetime of the
recipient. Such a burden imposes a "replicative stress" on
hematopoietic stem/progenitor cells. Superficially, hematopoietic
reconstitution after HSCT appears complete, with peripheral
blood cell counts and bone marrow cellularity normalizing in most
recipients within a few months of transplantation. However, studies of
recipients' hematopoietic progenitors, defined functionally (according
to clonogenic potential) or phenotypically (according to surface
antigen expression), have revealed marked deficits persisting for more
than 10 years after HSCT.1-5
Most human hematopoietic stem/progenitor cells express the CD34
antigen.6 Most primitive hematopoietic progenitors, and virtually all CD34+ HSCs, are contained within the
CD90+ subset.7-10 Although markedly enriched
for primitive progenitors, the CD34+CD90+
population is heterogeneous and contains some lineage-committed progenitors. Most lineage-committed progenitors, however, reside in the
larger CD34+CD90 In recent years, we and others have noted excessive telomere shortening
in leukocytes of HSCT recipients.12-19 Telomeres, the nonencoding regions of DNA at each end of eukaryotic chromosomes, consist of stereotyped oligonucleotide repeats and associated protein.20 They shorten with each round of mitosis in
normal human somatic cells, in contrast to the encoding DNA
sequences.20 Such shortening is due to the "end
replication problem," whereby a stretch of DNA is lost from the 5'
end of each new DNA strand.21 This DNA loss is estimated
at 40 to 120 base pairs (bp) per division.20 Thus,
telomeres have been likened to a "mitotic clock."22 The ribonucleoprotein reverse transcriptase, telomerase, may restore telomere length.23 It is variably present in hematopoietic
progenitors and in monocytes and lymphocytes,24 but in
these cells its presence does not completely attenuate telomere
shortening.25,26 Cross-sectional studies of healthy
subjects older than 4 years have shown a yearly decrease in peripheral
blood leukocyte telomere length of approximately 30 to 60 bp.13,26-28 It has been inferred that this decrease
represents the yearly aggregate telomere loss in HSCs.
Excessive leukocyte telomere shortening has been observed in virtually
all short- and long-term survivors of autologous and allogeneic HSCTs
studied and has amounted to between 300 and 2000 bp.12-19
It occurs in neutrophils, monocytes, and T cells.12,16,19 Notaro et al12 found an inverse relationship between the
extent of post-HSCT telomere loss and the number of nucleated cells in the graft. Another study found a correlation between donor age and the
extent of telomere shortening in allogeneic recipients.14 Other studies have failed to identify these, or any other,
associations.13,15,16 Most investigators have invoked HSC
replicative stress as the cause of HSCT-induced accelerated telomere
shortening. Some have concluded that transplantation induces
accelerated HSC "aging." Direct study of telomere changes in HSCs
has been precluded by our current technical inability to isolate a pure
HSC population for analysis.
HSC behavior can be studied indirectly by examining X chromosome
inactivation ratios in circulating leukocytes of female
subjects.29-31 Polymorphisms existing at distinct loci on
the X chromosome can be used to distinguish paternally and maternally
derived X chromosomes. The active and inactive X chromosome can be
distinguished by differential DNA methylation patterns at these
loci.32 The human androgen receptor (HUMARA) locus has
been useful, because it is amenable to polymerase chain reaction
(PCR)-based analysis, and approximately 90% of women are heterozygous
and, therefore, informative.31,32 Skewed X-inactivation
ratios (arbitrarily defined as inactivation of one allele in more than
75% of cells) have been demonstrated in leukocytes of hematologically
normal women. The incidence of such skewing rises with
age.31 It is likely that most cases of acquired skewing in
apparently healthy individuals are due to a growth advantage conferred
by parent-specific X-linked alleles (hemizygous
selection),33 although other causes, such as stem cell
depletion and the expansion of premalignant clones, have been
suggested.29,34 Autologous HSCT experiments in female Safari cats have shown that low stem cell doses can result in skewed
X-inactivation ratios, suggestive of oligoclonal hematopoiesis, and an
extended period of clonal instability after
transplantation.29 Polyclonal hematopoiesis has been
demonstrated in most human allogeneic HSCT recipients
studied.18,35,36
The central aim of this study was to investigate the fate of HSCs in
human allogeneic HSCT recipients. Because these cells are currently not
amenable to direct study, surrogate markers of HSC behavior were
examined. Specifically, we determined the kinetics of telomere
shortening in neutrophils in the year after HSCT and sought
correlations with changes in X-inactivation ratios and in the mitotic
activity of CD34+CD90+ and
CD34+CD90 Patients and transplantation characteristics
The median age of the recipients was 49 years (range, 11 to 58). The
indications for HSCT were chronic myelogenous leukemia in 7 patients,
acute myelogenous leukemia in 6, non-Hodgkin lymphoma in 5, acute
lymphoblastic leukemia in 2, myelodysplasia in 2, acute prolymphocytic
leukemia in 1, chronic lymphocytic leukemia in 1, and myelofibrosis in
1. The median age of the donors was 45 years (range, 10 to 64). All
donors were hematologically normal as established by history,
examination of peripheral blood cell counts, and bone marrow morphology.
Patients and donors underwent serologic typing for human leukocyte
antigens (HLA) A and B and high-resolution molecular HLA-DRB1 typing.
Twenty-two donor/recipient pairs were fully HLA-matched, and 3 (D/R11,
D/R13, and D/R21) were mismatched for one antigen. All patients
received myeloablative conditioning: 14 with busulphan and
cyclophosphamide37 and 11 with radiation-based
regimens.38 Hematopoietic cytokines were not administered
to bone marrow donors before harvest. Twenty-four patients received
bone marrow grafts; one received mobilized peripheral blood. The donor
of mobilized peripheral blood (D19) was mobilized with recombinant
human granulocyte colony-stimulating factor administered for 5 days (5 µg/kg/d), with apheresis performed on days 4 and 5. Grafts were not
T-cell depleted and contained a median of 2.8 × 108
nucleated cells per kilogram recipient weight (range, 1 to
6.8 × 108). Three recipients received granulocyte
colony-stimulating factor after HSCT (5 µg/kg/d): R12 from day +1
until the second of 2 consecutive days with an absolute neutrophil
count (ANC) more than 1.0 × 109/L, R9 from day +28 until
day +38 because of delayed engraftment, and R13 from day +13 to day +20
in the setting of severe sepsis. Cyclosporine and short-course
methotrexate were used in all patients for graft-versus-host disease
(GVHD) prophylaxis.38 Clinical grading of acute GVHD was
performed according to the criteria of Glucksberg et al,39
and chronic GVHD was diagnosed and classified according to standard
criteria.40 Twenty-two recipients were followed until time
of death or 1 year after HSCT. The other 3 (R23-R25) were studied in
greater detail immediately after engraftment and were followed for 60 days. Four patients died: R1 and R22 because of relapse at 176 and 233 days, respectively; R16 because of complications of chronic GVHD at 248 days; and R21 from regimen-related toxicity at 38 days.
Specimen collection
Cell processing and DNA extraction
Chimerism studies Leukocyte DNA was extracted and amplification of 8 microsatellite regions was performed by PCR, as described.41 After gel electrophoresis, hematopoietic chimerism was determined by comparing the size of amplified bands from the recipient at the time of blood sampling after HSCT with the size of bands from donor and recipient samples before HSCT. The test allows detection of admixtures of donor and recipient DNA down to the level of 5% to 10%.Measurement of mean terminal restriction fragment length of neutrophils Genomic DNA was digested by using the restriction enzymes RsaI and HinfI. The completeness of digestion was confirmed by electrophoresis and visualization of aliquots (1 µg) on ethidium bromide-stained 0.8% agarose minigels. Digested DNA (3 µg) was loaded into 0.5% agarose gels and electrophoresed overnight alongside a 32P-labeled size marker ( HIII). Samples from
donor/recipient pairs were run in adjacent lanes in the same gel. After
drying, denaturing, and neutralization, gels were hybridized to a
 -32P end-labeled 5'-(CCCTAA)3 telomeric
probe at 37°C overnight, as described.13,16 Gels were
then washed in decreasing concentrations of sodium chloride/sodium
citrate and exposed to a PhosphorImager plate (Molecular Dynamics,
Sunnyvale, CA). Lanes from representative gels are shown in Figure
2. Each terminal restriction fragment (TRF) smear was quantified by densitometry with the use of ImageQuant software (Molecular Dynamics) by an investigator blinded to the identity of samples. Mean TRF length was calculated as previously described,13,16 using the following equation: mean TRF
length =  (ODi × MWi)/(ODi)
where ODi is the optical density at position "i," and
MWi is the molecular weight of DNA at point "i." Mean TRF lengths were corrected for the running of inter-gel control samples, as previously described.26 Paired control samples
were run in adjacent lanes of 15 gels to establish methodologic
variance in determination of differences in mean TRF length; derived
differences between these control samples varied by 93 ± 59 bp.
Thus, the smallest true difference in mean TRF length reliably detected by this method was 270 bp (the mean + 3 SD of the variance
observed among paired controls).12
X-inactivation analysis with the HUMARA assay Neutrophil DNA was digested with RsaI or RsaI/HpaII (digest 2) at 37°C overnight. Restriction enzymes were inactivated at 65°C for 10 minutes. Digested DNA (50 ng) was added to a PCR mix (containing buffer, primer HUMARA I, primer HUMARA II, platinum Taq, and water) and amplified on a programmable thermal cycler. The PCR product was then mixed with deionized formamide and the GeneScan 500 TAMRA size standard (Applied Biosystems, Foster City, CA) and denatured at 95°C for 10 minutes. After rapid cooling, the denatured PCR product was run on an automated sequencer (PerkinElmer 310 CE; PerkinElmer, Shelton, CT) for sequence detection. Fragment sizes and peak heights were determined automatically by using GeneScan Analysis 3.1.2 and Genotyper 2.5 software (Applied Biosystems). Fragment peaks from a representative series are shown in Figure 3. Samples were deemed noninformative if only one allele was identified. In informative samples, the shorter of the 2 alleles was termed "allele 1," according to convention. The ratio between the 2 alleles (allele 1:allele 2) was measured for each sample. The allelic ratio was defined as the ratio between expressions of the 2 alleles and was corrected for potential preferential amplification of one of the alleles by dividing the allelic ratio of the precut sample by the allelic ratio of the non-precut sample of the same specimen (Figure 3). Allelic ratios of 3.0 and 0.33 both describe a 75%/25% split in X-inactivation in a given cellular population, but allele 1 is dominant in the first instance and allele 2 is dominant in the second. Excessive skewing was defined as an allelic ratio more than 3.0 or less than 0.33 (corresponding to > 75% expression of one allele).31
Isolation of CD34+ cells and fluorescence-activated
sorting of CD34+CD90+ and
CD34+CD90  cells were sorted on a FACSVantage
(Becton Dickinson Immunocytometry Systems, San Jose, CA) cell sorter
equipped with Coherent Enterprise (Innova Technologies, Palo Alto, CA)
and Helium-Neon (Spectra-Physics, Mountain View, CA) lasers. Small
aliquots of sorted cells were reanalyzed to establish sort purity,
which always exceeded 94%.
Assessment of cell cycle status of
CD34+CD90+ and
CD34+CD90 cells were incubated with 1 µg/mL
Hoechst 33342 (Sigma, St Louis, MO) (binds DNA) in Hoechst buffer (Hanks balanced salt solution, 20 mM HEPES pH 7.2, glucose 1 g/L, and
10% fetal bovine serum) at 37°C for 45 minutes. Samples were then
incubated with 1 µg/mL pyronin Y (Sigma) (binds RNA) at 37°C for 45 minutes. After one wash in RPMI containing 10% fetal bovine serum at
4°C, cells were resuspended in Hoechst buffer, and the cell cycle
status of these subsets was ascertained by flow cytometry, as
described.44,45 A mean of 1035 events (range, 300 to 2960) were gated for CD34+CD90+ cells. Results of
cell cycle analysis of donors' (D1-D14) cells and of recipients'
(R1-R8 and R16-R18) cells tested at 2 and 6 months after HSCT have been
previously published.11 Control experiments performed to
validate G0/G1 discrimination have been previously reported.43 Representative dot plots from a
donor/recipient pair are shown in Figure
4.
Statistical analysis Changes in neutrophil telomere length and cycling of marrow progenitors are expressed as mean ± SD. Two-tailed paired Student t tests were used to compare donor and recipient telomere lengths and progenitor cycling status. Linear regression analysis was used to explore the relationship between changes in telomere length over time within recipients. To discern whether a nonlinear or seemingly random relationship was evident, we plotted residuals (the difference between the actual and predicted value for each observation) against time and checked for a systematic pattern. Univariable analyses were then performed to search for predictors of the extent of telomere loss in recipients at 12 months after HSCT and for predictors of the pattern of telomere loss over the 12 months. Donor age, nucleated cell dose, the extent of GVHD, and the proportion of CD34+CD90+ progenitors in S/G2/M in recipients were examined in multivariable models. All analyses were performed by using the SAS statistical program (SAS-PC, Version 8.0; SAS Institute, Cary, NC).
Chimerism and recovery of peripheral blood cell counts All HSCT recipients were complete hematopoietic chimeras (> 90% donor hematopoiesis) at the time each blood and bone marrow sample was obtained after HSCT, as determined by analysis of donor- and recipient-specific microsatellite DNA markers.In all but one patient, the ANC recovered to more than 0.5 × 109/L before day +28. In R9, neutrophil engraftment did not occur until day +34. One recipient (R23) was mildly neutropenic at 2 months, and another (R18) at 6 months after HSCT; neutrophil counts were otherwise in the normal range from 2 to 12 months after HSCT in this cohort. Sustained platelet engraftment (defined as transfusion-independent platelet counts of more than 20 × 109/L) occurred in 23 patients after a median of 23 days (range, 13 to 63); it had not occurred in R21 and R22 at the time of their deaths 38 and 232 days after HSCT, respectively. All surviving recipients were platelet transfusion-independent at 6 and 12 months of follow-up. Changes in neutrophil telomere length Overall, the mean TRF length in recipients' neutrophils was significantly shorter than in their respective donors at engraftment ( 424 ± 350 bp; P < .0001), 6 months (495 ± 436
bp; P < .0001), and 12 months (565 ± 420 bp;
P < .0001) after HSCT. The degree of telomere shortening at 2 months after HSCT (325 ± 520 bp) did not achieve statistical
significance (P = .054); however, only 12 of 24 surviving
recipients were tested at this time.
Considering recipient telomere length in isolation from donor values,
there was no significant difference between telomere length at
engraftment, 2, 6, and 12 months by paired t tests, and the
slope of the regression line derived from these telomere lengths was
not significantly different from zero (P = .16). To determine if a nonlinear model would fit the data better, residuals from the regression line expressing change in telomere length were
plotted against time; their random distribution suggested random
determination of the pattern of change in telomere length. The pattern
of change in the mean TRF length of each recipient is shown in Figure
5. The variation among this cohort was
striking. Many recipients showed marked fluctuations in telomere length over the 12-month period of observation; in some, pronounced
fluctuations were observed in the first 60 days after HSCT (Figure 5F).
In 5 instances, telomere lengths exceeding donor values were
transiently recorded in recipients (R2, R3, R4, R8, and R9). Six
recipients (R1, R10, R13, R14, R17, and R21) showed no significant
change from donor telomere length over the period of follow-up.
By using univariable and multivariable linear regression, we sought associations between the degree of telomere shortening at 12 months and donor age, nucleated cell dose, the extent of GVHD, and the proportion of CD34+CD90+ progenitors in S/G2/M after HSCT. No associations were identified. In addition, univariable and multivariable analyses were performed to assess for associations between these factors and the pattern of change in telomere length. For these analyses, recipients were divided into 2 groups ("positive" and "negative") for each of 2 categorical features of the pattern of change: significant telomere loss (> 270 bp) at any time over the 12 months of follow-up, and significant fluctuation (> 270 bp) in telomere length over the 12 months. Again, no associations were identified. Stability of X-inactivation ratios Fourteen recipients had a female donor; 11 of these were informative at the HUMARA locus. X-inactivation ratios were nonskewed in 8, and skewed in 3 informative donors. As can be seen from Table 2, ratios in each recipient tended to show little variation over the period of observation. They approximated those in respective donors, with the same allelic dominance. Two recipients (R1 and R5) with nonskewed donors with X-inactivation ratios close to 3:1 had ratios that exceeded 3:1 at 2 months and transiently at engraftment, respectively. There was no clear evidence for acquired oligoclonal hematopoiesis in any of this cohort of HSCT recipients.
Composition and cycling of CD34+ marrow progenitors CD90 expression among CD34+ marrow cells and progenitor cell cycling in 4 recipients at 2 months after HSCT were very similar to that observed in 8 recipients at 6 months. A single set of data was derived for the one recipient (R4) tested at both 2 and 6 months (by calculating the mean values), and results from all recipients from these 2 times were combined for the sake of analysis, as previously published.11In steady-state donor marrow, 20.3% ± 5.7% of CD34+ cells expressed the CD90 antigen. At 2 to 6 months after HSCT, this proportion was significantly lower (10.3% ± 4%; P = .01). By 12 months after HSCT, the proportion had fallen further to 5.6% ± 2.7% (P < .0001, compared with donors; P = .02, compared with 2-6 months). In donor marrow, CD34+CD90+ cells were more
quiescent than CD34+CD90
By examining surrogate markers of stem cell behavior in recipients of allogeneic HSCT, we sought to gain new insights into the processes of engraftment and early hematopoietic reconstitution in the clinical transplantation setting. We have demonstrated excessive neutrophil telomere shortening in fully engrafted recipients in the first year after HSCT. However, when recipient telomere length was considered in isolation from telomere length in donors, we found no consistent change in telomere length between 1 and 12 months after HSCT; many recipients had wide, and apparently random, fluctuations in telomere length during this time. The stochastic nature of these fluctuations contrasted strikingly with the consistency of trends in circulating blood cell counts, cycling kinetics of bone marrow progenitors, and X-inactivation ratios in neutrophils. Neutrophils were chosen for study because they are homogeneous, short-lived, and easily obtained. Unlike lymphocytes, they have no potential for significant postmaturational proliferation. On each occasion, we assessed the mean TRF length in DNA derived from at least 3 × 107 circulating neutrophils. It is most likely that this population contained progeny of the full complement of HSCs contributing to granulopoiesis at the time of sampling. The length of a neutrophil's telomeres is determined by several factors: (1) the telomere length in the HSC from which it is derived, (2) the number of cell divisions required to complete its development, (3) the extent of telomere loss with each round of mitosis, and (4) the degree of attenuation of telomere loss by telomerase. If an increase in the number of cell divisions from HSC to mature neutrophil were the sole factor underlying the excessive telomere shortening in HSCT recipients, we would have expected changes in telomere length to parallel changes in the mitotic activity of hematopoietic progenitors. No such relationship was demonstrated. We did not measure telomerase activity in marrow progenitors in this study and, therefore, cannot exclude impaired telomerase expression or function as a cause of the telomere shortening. However, there is indirect evidence to suggest that telomerase activity may be normal or up-regulated in HSCT recipients. Telomerase has been found to be up-regulated in response to ex vivo expansion of hematopoietic progenitors25,46 and in the setting of accelerated telomere shortening in Fanconi anemia47 and HIV infection.48 Although there are no strong grounds to suspect telomerase dysfunction after HSCT, the demonstration of excessive telomere shortening in more than one hematopoietic lineage of HSCT recipients in previous studies16,19 strongly suggests excessive telomere loss occurring at the level of the pluripotent stem cell. It is likely that accelerated HSC proliferation is the dominant cause of the telomere shortening we observed in these HSCT recipients. Few studies have prospectively assessed changes in leukocyte telomere
length within healthy subjects. Aside from age-associated decline,
telomere length has fluctuated over time in most leukocyte subsets
studied.19,49,50 In the setting of steady-state
hematopoiesis and constant rates of postmaturational telomere loss,
true fluctuations (ie, those exceeding the method's limit of detection
of approximately 300 bp) can be attributed to differences in the clonal
origin of the cells analyzed. We did not track changes in telomere
length in the marrow donors in this study, and, therefore, lack a
rigorous control for variation in telomere length over the 12-month
period. However, the fluctuations in telomere length in many recipients were particularly striking when compared with the limited data for
leukocytes of normal individuals19,49,50 Some cross-sectional studies of allogeneic HSCT recipients have suggested that nucleated cell dose12 and donor age14 can affect the extent of telomere loss, and it is conceivable that GVHD-associated immune assault on hematopoietic cells could affect telomere loss. In this cohort, we sought associations between these transplant-related factors and both the extent and pattern of telomere shortening and found none in univariable or multivariable analyses. It is possible that other factors, such as infection, drugs, and cytokine administration, may influence the extent and pattern of telomere loss, but in this small and heterogeneous cohort it was not feasible to test for all potential interactions. Given the weight of evidence for stochastic determination of HSC behavior,30 we believe it is likely that the pattern of telomere loss was determined randomly. The lack of correlation between the extent of leukocyte telomere shortening and time from HSCT has been a consistent finding in previous studies.12-19 This finding implies that HSCT-induced acceleration in leukocyte telomere loss is neither progressive nor sustained. One recent longitudinal study that specifically addressed the kinetics of telomere shortening after HSCT was that of Rufer et al.19 They examined telomere length in monocytes and lymphocytes obtained from 4 allogeneic HSCT recipients up to 12 years after HSCT and found that telomeres in the recipients shortened at a comparable rate to that of their donors from the second year after HSCT. This finding led them to suggest that acceleration in telomere shortening was limited to the first year after HSCT. We found that many recipients entered their second year after HSCT with no evidence of sustained acceleration in telomere loss, in accordance with the findings of Rufer et al.19 Two other groups have recently presented preliminary results of prospective analyses of changes in leukocyte telomere length in HSCT recipients.51,52 Like us, they found wide variation in the pattern of telomere changes. That clonal instability could reflect small HSC numbers was elegantly demonstrated by Abkowitz et al29 through studies of X-inactivation ratios in transplanted Safari cats and computer modeling of HSC behavior.30 In their longitudinal studies of hematologically normal women, Prchal et al53 established that X-inactivation ratios remained remarkably constant in multiple blood lineages over a period of 2 to 3 years. Furthermore, they estimated the number of HSCs required to be actively engaged in hematopoiesis to ensure ratio stability. Of note, their model did not take into account the effects of hemizygous selection. The relative constancy in X-inactivation ratios observed in this cohort of HSCT recipients suggests the active involvement of a sufficient number of HSCs in granulopoiesis to ensure ratio stability. The X-inactivation ratio that has been widely used to define the limit of polyclonal hematopoiesis, 3:1, was only marginally exceeded in 2 recipients with donors exhibiting nonskewed ratios. We are reluctant to infer the development of oligoclonal hematopoiesis from these 2 isolated results, because all other X-inactivation ratios obtained in these 2 donor/recipient pairs were very close to this arbitrary cutoff. Recipients of grafts from donors with skewed ratios tended to exhibit skewing to the same extent, and with the same dominant allele as their donors. If hemizygous selection is the cause of most cases of acquired ratio skewing in apparently healthy older women, as suggested,33 then it appears to be manifested similarly in human HSC-replete marrow donors and their comparatively HSC-deficient engrafted recipients. We used indirect methods to assess HSC behavior. The advantage of these methods is that a global picture of HSC activity may be captured. A more direct method involves marking HSCs with retroviral vectors and following the fate of specific clones distinguished by their possession of unique proviral insertion sites. Recently, Kim et al54 showed in Rhesus macaques that hematopoiesis was polyclonal in the first year after autologous HSCT. Analysis of individual clones in colony-forming units on multiple occasions in the first year showed that several clones contributed for prolonged periods. By tracking the function of individual clones of genetically marked human severe combined immunodeficient (SCID)-repopulating cells (SRCs) in nonobese diabetic (NOD)-SCID mice, Guenechea et al55 observed marked variation in the timing of appearance, life span, proliferative capacity, and self-renewal potential of individual SRC clones. They concluded that their data supported the existence of discrete human HSCs with short- or long-term repopulating capabilities. There is strong data to support the existence of these cells among murine HSCs.56 Our study, with its absence of a gene-marking component, clearly has little to add to the ongoing debate about the existence of short-term and long-term repopulating cells in humans. However, their existence would have profound implications for the interpretation of our results. If Guenechea et al55 are correct in their assumption that human long-term repopulating cells read out after 3 months in NOD-SCID mice, then we may have captured the activity of both short-term and long-term repopulating cells in this study. Most importantly, we believe that the highly variable nature of HSC behavior after HSCT revealed by the studies of Kim et al54 and Guenechea et al55 and by our own observations in these human HSCT recipients constitutes increasingly strong evidence for stochastic determination of HSC contribution to mature blood cell formation and hematopoietic reconstitution after HSCT. Drawing on all our data, we propose the following paradigm for early
hematopoietic reconstitution after human allogeneic HSCT. Immediately
after grafting, maximal proliferation of donor HSCs is induced in the
myeloablated recipient and results in accelerated telomere loss. The
contribution of individual HSCs to active hematopoiesis (through
differentiation) or hematopoietic repopulation (through extensive
self-renewal) is determined stochastically. When HSCs with shortened
telomeres contribute to granulopoiesis, the accelerated telomere loss
may be detected in circulating neutrophils. Over the next 2 to 6 months, the number of HSC clones contributing to mature blood cell
formation is significantly reduced compared with normal numbers, as
evidenced by a propensity for marked fluctuations in neutrophil
telomere length and a nearly 4-fold increase in the mitotic rate of
CD34+CD90+ marrow progenitors. However, the
threshold HSC number that would be expected to result in significant
variation in X-inactivation ratios is seldom crossed. By 12 months, a
significant degree of hematopoietic repopulation has been accomplished.
The mitotic rate of CD34+CD90+ bone marrow
progenitors, although still significantly higher than in steady-state
marrow, is lower than at 2 to 6 months after HSCT because more HSC
clones are now contributing to mature blood cell formation at any given
time. HSC proliferative rates have slowed, and leukocyte telomere loss
is no longer accelerated. However, a marked reduction in the proportion
of CD34+ cells expressing the CD90 antigen betrays a
persistent proximal hematopoietic deficit To conclude, there is now strong evidence that HSCT-induced accelerated telomere loss, occurring at the HSC level, is finite in terms of duration and magnitude. Here, and in 2 previous studies,13,16 we have shown HSCT-induced telomere loss of 400 to 600 bp. This magnitude of telomere loss is within the normal interindividual range at any given age13,26-28 and may be less than the normal telomere loss experienced in the first year of life.26,51,57,58 Thus, it is unlikely to pose a threat to graft survival or appreciably increase the risk of donor-derived clonal hematopoietic disorders in most allogeneic recipients. Our results provide further indirect evidence for stochastic stem cell behavior in HSCT recipients, underscoring the importance of maximizing transfection and sustained transgene expression in gene therapy protocols. With regards to the clinical-grade ex vivo expansion of HSCs, a note of caution is warranted. The demonstration that telomere length in a population of CD34+ cells is unaffected by 2 weeks of ex vivo culture46 should not be taken as evidence for maintenance of telomere length in HSCs. HSCs constitute such a small minority of the cells assayed that any change in their telomere length will not affect the mean TRF length of the population as a whole. The change will only be detected when large numbers of their progeny are tested. Stochastic HSC behavior in vivo may ensure the relative protection of a proportion of stem cells from the burden of HSCT-induced replicative stress. With ex vivo culture techniques capable of inducing proliferation of all repopulating cells in a very short space of time,59 we must be careful not to overly stress an entire population of HSCs before it has begun its work in a myeloablated recipient. Markers of HSC replicative stress should be monitored very closely in this setting.
We thank Roxanne Macaskill and Martha Rolland for support; Elizabeth Sexsmith, Susan Chilton-MacNeill, Jodi Lees, Nazir Jamal, and Wilma Vanek for invaluable technical assistance; Peter Ray for chimerism studies; and David Malkin for providing equipment and space.
Submitted August 16, 2001; accepted November 29, 2001.
Supported by an award from the Aplastic Anemia Association of Canada and a Seed Grant from the Hospital for Sick Children Research Institute. I.T. was supported by a Young Investigator Award from the American Society of Clinical Oncology and a Duncan L. Gordon Fellowship from the Hospital for Sick Children Foundation. L.S. is supported by a Canadian Institutes of Health Research postdoctoral Fellowship.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Hans A. Messner, Department of Medical Oncology and Hematology, Rm 5107, 610 University Ave, Toronto, Ontario M5G 2M9, Canada; e-mail: hans.messner{at}uhn.on.ca.
1.
Messner HA, Curtis JE, Minden MD, et al.
Clonogenic hemopoietic precursors in bone marrow transplantation.
Blood.
1987;70:1425-1432 2. Ma DD, Varga DE, Biggs JC. Haemopoietic reconstitution after allogeneic bone marrow transplantation in man: recovery of haemopoietic progenitors (CFU-Mix, BFU-E and CFU-GM). Br J Haematol. 1987;65:5-10[Medline] [Order article via Infotrieve]. 3. Novitzky N, Mohammed R. Alterations in the progenitor cell population follow recovery from myeloablative therapy and bone marrow transplantation. Exp Hematol. 1997;25:471-477[Medline] [Order article via Infotrieve]. 4. Podesta M, Piaggio G, Frassoni F, et al. Deficient reconstitution of early progenitors after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1997;19:1011-1017[CrossRef][Medline] [Order article via Infotrieve]. 5. Selleri C, Maciejewski JP, De Rosa G, et al. Long-lasting decrease of marrow and circulating long-term culture initiating cells after allogeneic bone marrow transplant. Bone Marrow Transplant. 1999;23:1029-1037[CrossRef][Medline] [Order article via Infotrieve]. 6. Civin CI, Trischmann MJ, Fackler MJ, et al. Report on the CD34 cluster workshop. In: Knapp W, ed. Leucocyte Typing IV. Oxford United Kingdom: Oxford University Press; 1989:818-825.
7.
Baum CM, Weissman IL, Tsukamoto AS, Buckle AM, Peault B.
Isolation of a candidate human hematopoietic stem-cell population.
Proc Natl Acad Sci U S A.
1992;89:2804-2808
8.
Craig W, Kay R, Cutler RL, Lansdorp PM.
Expression of Thy-1 on human hematopoietic progenitor cells.
J Exp Med.
1993;177:1331-1342
9.
Murray L, Chen B, Galy A, et al.
Enrichment of human hematopoietic stem cell activity in the CD34+Thy-1+Lin 10. Negrin RS, Atkinson K, Leemhuis T, et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant. 2000;6:262-271[CrossRef][Medline] [Order article via Infotrieve].
11.
Thornley I, Sutherland DR, Nayar R, Sung L, Freedman MH, Messner HA.
Replicative stress after allogeneic bone marrow transplantation: changes in cycling of CD34+CD90+ and CD34+CD90
12.
Notaro R, Cimmino A, Tabarini D, Rotoli B, Luzzatto L.
In vivo telomere dynamics of human hematopoietic stem cells.
Proc Natl Acad Sci U S A.
1997;94:13782-13785 13. Wynn RF, Cross MA, Hatton C, et al. Accelerated telomere shortening in young recipients of allogeneic bone marrow transplants. Lancet. 1998;351:178-181[CrossRef][Medline] [Order article via Infotrieve]. 14. Akiyama M, Hoshi Y, Sakurai S, Yamada H, Yamada O, Mizoguchi H. Changes of telomere length in children after hematopoietic stem cell transplantation. Bone Marrow Transplant. 1998;21:167-171[CrossRef][Medline] [Order article via Infotrieve]. 15. Lee JJ, Kook H, Chung IJ, et al. Telomere length changes in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24:411-415[CrossRef][Medline] [Order article via Infotrieve]. 16. Wynn RF, Thornley I, Freedman MH, Saunders EF. Telomere shortening in leucocyte subsets of long-term survivors of allogeneic bone marrow transplantation. Br J Haematol. 1999;105:997-1001[CrossRef][Medline] [Order article via Infotrieve]. 17. Akiyama M, Asai O, Kuraishi Y, et al. Shortening of telomeres in recipients of both autologous and allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2000;25:441-447[CrossRef][Medline] [Order article via Infotrieve].
18.
Mathioudakis G, Storb R, McSweeney PA, et al.
Polyclonal hematopoiesis with variable telomere shortening in human long-term allogeneic marrow graft recipients.
Blood.
2000;96:3991-3994
19.
Rufer N, Brummendorf TH, Chapuis B, Helg C, Lansdorp PM, Roosnek E.
Accelerated telomere shortening in hematological lineages is limited to the first year following stem cell transplantation.
Blood.
2001;97:575-577 20. McEachern MJ, Krauskopf A, Blackburn EH. Telomeres and their control. Annu Rev Genet. 2000;34:331-358[CrossRef][Medline] [Order article via Infotrieve]. 21. Olovnikov AM. A theory of marginotomy: the incomplete copying of template margin in enzymatic synthesis of polynucleotides and biological significance of the phenomenon. J Theor Biol. 1973;41:181-190[CrossRef][Medline] [Order article via Infotrieve].
22.
Vaziri H, Dragowska W, Allsopp RC, Thomas TE, Harley CB, Lansdorp PM.
Evidence for a mitotic clock in human hematopoietic stem cells: loss of telomeric DNA with age.
Proc Natl Acad Sci U S A.
1994;91:9857-9860
23.
Bodnar AG, Ouellette M, Wright WE, et al.
Extension of life span by introduction of telomerase into normal cells.
Science.
1998;279:349-352 24. Hiyama K, Hirai Y, Shay JW, et al. Activation of telomerase in human lymphocytes and progenitor cells. J Immunol. 1995;155:3711-3715[Abstract].
25.
Engelhardt M, Kumar R, Albanell J, Pettengell R, Han W, Moore MA.
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cells.
Blood.
1997;90:182-193 26. Robertson JD, Gale RE, Wynn RF, et al. Dynamics of telomere shortening in neutrophils and T lymphocytes during ageing and the relationship to skewed X chromosome inactivation patterns. Br J Haematol. 2000;109:272-279[CrossRef][Medline] [Order article via Infotrieve]. 27. Vaziri H, Schachter F, Uchida I, et al. Loss of telomere DNA during ageing of normal and trisomy 21 human lymphocytes. Am J Hum Genet. 1993;52:661-667[Medline] [Order article via Infotrieve].
28.
Ball SE, Gibson FM, Rizzo S, Tooze JA, Marsh JCW, Gordon-Smith EC.
Progressive telomere shortening in aplastic anemia.
Blood.
1998;91:3582-3592
29.
Abkowitz JL, Persik M, Shelton G, et al.
Behavior of hematopoietic stem cells in a large animal.
Proc Natl Acad Sci U S A.
1995;92:2031-2035 30. Abkowitz JL, Catlin SN, Guttorp P. Evidence that hematopoiesis may be a stochastic process in vivo. Nat Med. 1996;2:190-197[CrossRef][Medline] [Order article via Infotrieve].
31.
Busque L, Mio R, Mattioli J, et al.
Nonrandom X-inactivation patterns in normal females: lyonization ratios vary with age.
Blood.
1996;88:59-65 32. Allen RC, Zoghbi HY, Moseley AB, Rosenblatt HM, Belmont JW. Methylation of HpaII and HhaI sites near the polymorphic CAG repeat in the human androgen receptor gene correlates with X-chromosome inactivation. Am J Hum Genet. 1992;51:1229-1239[Medline] [Order article via Infotrieve].
33.
Abkowitz JL, Taboada M, Shelton GH, Catlin SN, Guttorp P, Kiklevich JV.
An X chromosome gene regulates hematopoietic stem cell kinetics.
Proc Natl Acad Sci U S A.
1998;95:3862-3866 34. Busque L, Gilliland DG. X-inactivation analysis in the 1990s: promise and potential problems. Leukemia. 1998;12:128-135[CrossRef][Medline] [Order article via Infotrieve].
35.
Nash R, Storb R, Neiman P.
Polyclonal reconstitution of human marrow after allogeneic bone marrow transplantation.
Blood.
1988;72:2031-2037 36. Turhan AG, Humphries R, Phillips G, Eaves A, Eaves C. Clonal hematopoiesis demonstrated by DNA polymorphisms after allogeneic bone marrow transplantation. N Engl J Med. 1989;320:1655-1661[Abstract].
37.
Tutschka PJ, Copelan EA, Klein JP.
Bone marrow transplantation for leukemia following a new busulfan and cyclophosphamide regimen.
Blood.
1987;70:1382-1388 38. Curtis JE, Messner HA. Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility. Can Med Assoc J. 1982;126:649-655[Abstract]. 39. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestation of graft-versus-host disease in human recipients of marrow from HLA-matched sibling donors. Transplantation. 1974;18:295-304[Medline] [Order article via Infotrieve]. 40. Atkinson K, Horowitz MM, Gale RP, Lee MB, Rimm AA, Bortin MM. Consensus among bone marrow transplanters for diagnosis, grading and treatment of chronic graft-versus-host disease. Bone Marrow Transplant. 1989;4:247-254[Medline] [Order article via Infotrieve]. 41. Lins AM, Micka KA, Sprecher CJ, et al. Development and population study of an eight-locus short tandem repeat (STR) multiplex system. J Forensic Sci. 1998;43:1168-1180[Medline] [Order article via Infotrieve]. 42. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34+ cell determination by flow cytometry. J Hematother. 1996;3:213-226. 43. Gratama JW, Keeney M, Sutherland DR. Enumeration of CD34+ hematopoietic stem and progenitor cells. Current Protocols in Cytometry. 1999;6.4:1-22. 44. Thornley I, Nayar R, Freedman MH, et al. Differences in cell cycle kinetics of candidate engrafting cells in human bone marrow and mobilized peripheral blood. Exp Hematol. 2001;29:525-533[CrossRef][Medline] [Order article via Infotrieve].
45.
Gothot A, Pyatt R, McMahel J, Rice S, Srour EF.
Functional heterogeneity of human CD34+ cells isolated in subcompartments of the G0/G1 phase of the cell cycle.
Blood.
1997;90:4384-4393 46. Kobari L, Pflumio F, Giarratana M, et al. In vitro and in vivo evidence for the long-term multilineage (myeloid, B, NK, and T) reconstitution capacity of ex vivo expanded human CD34+ cord blood cells. Exp Hematol. 2000;28:1470-1480[CrossRef][Medline] [Order article via Infotrieve]. 47. Leteurtre F, Li X, Guardiola P, et al. Accelerated telomere shortening and telomerase activation in Fanconi's anaemia. Br J Haematol. 1999;105:883-893[CrossRef][Medline] [Order article via Infotrieve].
48.
Wolthers KC, Otto SA, Wisman GB, et al.
Normal T-cell telomerase activity and upregulation in human immunodeficiency virus-1 infection.
Blood.
1999;93:1011-1019
49.
Zeichner SL, Palumbo P, Feng Y, et al.
Rapid telomere shortening in children.
Blood.
1999;93:2824-2830
50.
Wolthers KC, Bea G, Wisman A, et al.
T cell telomere length in HIV-1 infection: no evidence for increased CD4+ T cell turnover.
Science.
1996;274:1543-1547 51. Roelofs H, de Pauw ESD, Tanke HJ, Willemze R, Fibbe WE. Telomere length homeostasis after allogeneic peripheral blood stem cell transplantation [abstract]. Blood. 2000;96:203a. 52. Engelhardt M, Guo Y, Finke J. Telomere shortening in hematopoietic cells of patients undergoing allogeneic stem cell transplantation [abstract]. Blood. 2000;96:762a.
53.
Prchal JT, Prchal JF, Belickova M, et al.
Clonal stability of blood cell lineages indicated by X-chromosomal transcriptional polymorphism.
J Exp Med.
1996;183:561-567
54.
Kim HJ, Tisdale JF, Wu T, et al.
Many multipotential gene-marked progenitor or stem cell clones contribute to hematopoiesis in nonhuman primates.
Blood.
2000;96:1-8 55. Guenechea G, Gan OI, Dorrell C, Dick JE. Distinct classes of human stem cells that differ in proliferative and self-renewal potential. Nat Immunol. 2001;2:75-82[CrossRef][Medline] [Order article via Infotrieve].
56.
Zijlmans JMJM, Visser JWM, Kleiverda K, Kluin PM, Willemze R, Fibbe WE.
Modification of rhodamine staining allows identification of hematopoietic stem cells with preferential short-term or long-term bone marrow-repopulating ability.
Proc Natl Acad Sci U S A.
1995;92:8901-8905
57.
Frenck RW Jr, Blackburn EH, Shannon KM.
The rate of telomere sequence loss in human leukocytes varies with age.
Proc Natl Acad Sci U S A.
1998;95:5607-5610
58.
Rufer N, Brummendorf TH, Kolvraa S, et al.
Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood.
J Exp Med.
1999;190:157-167 59. Young JC, Lin K, Hansteen G, et al. CD34+ cells from mobilized peripheral blood retain fetal bone marrow repopulating capacity within the Thy-1+ subset following cell division ex vivo. Exp Hematol. 1999;27:994-1003[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  G. M. Baerlocher, A. Rovo, A. Muller, S. Matthey, M. Stern, J. Halter, D. Heim, J. Rischewski, A. Gratwohl, and A. Tichelli Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex Blood, July 2, 2009; 114(1): 219 - 222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Vickers JAK2 617V>F positive polycythemia rubra vera maintained by approximately 18 stochastic stem-cell divisions per year, explaining age of onset by a single rate-limiting mutation Blood, September 1, 2007; 110(5): 1675 - 1680. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jaras, A. Edqvist, J. Rebetz, L. G. Salford, B. Widegren, and X. Fan Human short-term repopulating cells have enhanced telomerase reverse transcriptase expression Blood, August 1, 2006; 108(3): 1084 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Sieburg, R. H. Cho, B. Dykstra, N. Uchida, C. J. Eaves, and C. E. Muller-Sieburg The hematopoietic stem compartment consists of a limited number of discrete stem cell subsets Blood, March 15, 2006; 107(6): 2311 - 2316. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Bhatia, K. Van Heijzen, A. Palmer, A. Komiya, M. L. Slovak, K. L. Chang, H. Fung, A. Krishnan, A. Molina, A. Nademanee, et al. Longitudinal Assessment of Hematopoietic Abnormalities After Autologous Hematopoietic Cell Transplantation for Lymphoma J. Clin. Oncol., September 20, 2005; 23(27): 6699 - 6711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Roelofs, E. S. D. de Pauw, A. H. Zwinderman, S. M. Opdam, R. Willemze, H. J. Tanke, and W. E. Fibbe Homeostasis of telomere length rather than telomere shortening after allogeneic peripheral blood stem cell transplantation Blood, January 1, 2003; 101(1): 358 - 362. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
the fluctuation in R23 in the month after engraftment is a good example (Figure